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Introduction
My commentary is based on a study that we recently
completed under the aegis of the National Toxicology
Program (NTP). This study was an objective effort to
compare results ofin vitro tests, which measure muta-
genicity in two different systems or clastogenic effects,
either as chromosomal aberrations or as sister chro-
matid exchange, with chemicals that have been ade-
quately tested for carcinogenicity (1). We were able to
evaluate chemicals that have, in many cases, been the
same batches that were used in the two rodent species
for tumorigenicity studies. We were able to objectify
the study byconductingtheinvitro tests withprotocols
that were standardized to give reproducible results
within and between laboratories. Mostimportantly, the
assays were conducted on chemicals identified by code.
The value of the NTP tumorigenicity data base is
derived from the fact that it is one of the few sources
of results where animals are exposed under conditions
that will allow for the identification of no evidence of
carcinogenicity. There was atotal of73 chemicals in the
study group, 44 ofwhich were identified as carcinogens,
in that they induced some pattern oftumorigenicity in
at least one sex of either the rat or mouse strains that
were studied. These tumorigenicity results were then
compared both in a binary fashion, i.e., plus-minus
basis, and in more depth, with the results from in vitro
genetic toxicity tests.
The overall results ofthis study are given in Figure
1 to illustrate a couple of the important points. The
results aredividedintothosethat aremutagens orthose
that arenonmutagens; thosethat arecarcinogenicmuta-
gens and noncarcinogenic mutagens. The largest rela-
tive proportions of these 73 chemicals fall into the 3
groups represented by the mutagenic carcinogens and
the nonmutagenic noncarcinogens and nonmutagenic
carcinogens. The chemicals that induced mutagenicity
in this figure are based solely upon the results of tests
conducted in Salmonella. The substances that were
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FIGURE. 1. Seventy-three chemicals that have been assayed for car-
cinogenicity in two rodent species were evaluated for ability to
induce mutations in Salmonella. The proportions ofthe four con-
binations of responses are presented.
mutagenic but not carcinogenic represented only
approximately 20% of the total mutagens. Therefore,
an important conclusion to be derived from this study
is that the proportion of substances that are carcino-
genic but nonmutagenic is far greater than has been
reported from studies conducted elsewhere.
We believe that further evaluation ofchemicals that
represent mutagenic noncarcinogens can be construc-
tively approached by looking at the potential genetic
toxicity of these chemicals in in vivo systems. These
same 73 chemicals currently are being evaluated for
their clastogenic effects in vivo, also under code. We
will test the possibility that in vivo genetic toxicity
assays will be able to help to prospectively distinguish
betweensubstancesthatareinessencehazardousmuta-
gens and those that may be nonhazardous mutagens
because ofthe abilityoftherodentstoeithermetabolize
or dispose ofthem in a manner that does not give them
effective access to DNA.
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vitro tests is the inability to distinguish between the
carcinogenic nonmutagens andthenoncarcinogenic non-
mutagens. This represents a major blind spot.
Ithasbeen proposed that some combination(battery)
of in vitro assays would complement the Salmonella
assay inthe identification ofcarcinogens. Therefore, we
did a fairly extensive comparison with another muta-
genicity assay in mammalian cells, and assays for clas-
togenicity and sister chromatid exchange (SCE) induc-
tion. We also looked for the best of all the possible
combinations in comparison to the Salmonella mutagen-
esis assay for a variety ofparameters oftumorigenicity
responses. There are some subcategories ofthe tumor-
igenicresponsethatappeartobedefined moreprecisely
by a combination of tests, as opposed to a single Sal-
monella result (1). However, there is no real net gain
in information since the other three assays showed less
specificity. That is, the proportion of carcinogens iden-
tified relative to the number of noncarcinogens (false
positives) identified. So, in fact, there does not appear
to be an advantage in the use of a combination oftests
to distinguish carcinogens over the results obtained
from Salmonella alone. However, I am not precluding
other applications of these in vitro assays, and it is
possible that one might want to use a combination of
assays since the results from these various tests are
often concordant, reinforcing the fact that these tests
do identify mutagens. Therefore, the assays can play a
supplementary role when used in combination, butthey
do not appear to play a complementary role.
We are still faced with the issue of whether or not
we have really identified all of the potential mutagens
among these 73 chemicals or whether there are a num-
ber of nonmutagenic chemicals that are tumorigenic.
There is the implication that the Salmonella mutagen-
icity assay is functioning to detect a majority ofcarcin-
ogenic chemicals and that either by consequence ofthe
selection process that is involved in acquiringchemicals
for testing by the NTP, or by some other quirk, we
have identified a number of substances that are non-
mutagenic carcinogens. I would therefore like to focus
the discussion period around some questions that will
relate to either mutagenicity, carcinogenicity, or risk
assessment.
I would like to elicit response from the audience on
the proposition that if a battery of tests do not appar-
ently improve upon the performance of a Salmonella
assay, then are we faced with the possibility ofhaving
to operationally define all mutagens on the basis of a
Salmonella response. How, from a geneticist's view-
point, is this viewed? Further, for those chemicals that
have shown some dichotomous response, for example,
which showed a positive response in the mouse lym-
phoma assay, which measures mutation at the tk locus,
but were negative in Salmonella. How do we resolve
dichotomies between short-term test results? Do you
accept that Salmonella is detecting most mutagens?
And, if so, have we reached the limits of what we can
achieve in vitro in identifying potential mutagens?
In order to overcome some of the natural reticence
that we all have to engage in public exchange, I will
single one or two individuals out in the audience and
ask them to respond to these questions. I'd like to start
with a card-carrying geneticist and ask Dr. Larry Val-
covic.
Discussion
DR. LARRY VALCOVIC, FDA: In terns of the dis-
cordance, first of all, there is not much difference
between these tests. We could use any ofthose others
as saying, Is this test detecting most mutagens? The
fact that we do have a large Salmonella data base is a
compelling reason for focusing on Salmonella as our
baseline. I think Salmonella is probably detecting most
mutagens. However, some of the other factors deter-
mining the extent to which one would desire to use
supplementarytestsgobeyond simplydetectingwheth-
er a chemical does or does not have mutagenic activity.
The term that was used in the now 10-year-old
DHEW document on mutagenicity was "intrinsic muta-
genic activity." This involves questions ofhow mutants
behave and of mutant expression. This expands the
question, which implied only qualitative prediction. If
it's more thanjust the yes-no question, forexample, for
chromosome aberrations, we can learn somethingabout
translocations.
DR. TENNANT: Are you comfortable with accepting
the repeatable negative results from a Salmonella assay
that uses an S-9 as its exogenous source ofmetabolism?
DR. VALCOVIC: For what question?
DR. TENNANT: As a nonmutagen.
DR. VALCOVIC: As Sandy Miller was talking about
in his closing remarks, this whole area oftoxicity really
is reducing our levels of uncertainty or modifying our
levels of uncertainty. To a certain level, yes, the data
from most ofour experience is compelling. I think what
we need to do is get more specific in terms oftypes of
chemicals for which, in terms of carcinogenicity, the
discordance lies. Clearly, ifthe chemical falls into that
area for which there is discordance, then, yes, it's true
that that compound is not mutagenic in Salmonella. But
justlike allareas oftoxicology, wehaveto explore more
tests to find out more aboutthe nature ofthat chemical.
DR. TENNANT: Dr. Butterworth, couldyousharethat
opinion?
DR. BYRON BUTTERWORTH, CHEMICAL INDUSTRY
INSTITUTE OFTOXICOLOGY: I thinkthere arefairlysim-
ple answers for your questions. First ofall, how do we
define amutagen operationally as mutagenic in the Sal-
monella assay? Is Salmonelladetectingmostmutagens?
Yes, I think it is. Are we near the limits of what's
achievable in vitro? Yes. Very simple.
I think the problem is that we need to move into the
whole animal. The challenge really arises for genetic
toxicology to begin to identify those things that are
going on in the whole animal to help us predict carcin-
ogenicity. Mutagenicity is one thing, predicting poten-
tial carcinogens is another. There are many different
classes ofnongenotoxic carcinogens and we need to try
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to identify those and pick predictors that will indicate
their potential carcinogenicity. And, in point of fact,
very often this will only happen in the whole animal.
Forexample, saccharin produces tumors onlywhenyou
reach massive doses of 3000 mg/kg/day. Then you get
hyperplasia in the bladder. To me, that hyperplasia is
a good indicator ofpotential carcinogenicity. I think we
need to begin to look at the different types ofnongeno-
toxic carcinogens to help us as predictors. We can't mix
things like TCDD with saccharin because they act in
totally different ways. We can't mix the hypolipidemic
agents with some of the things that cause tumors in
male rat kidneys because they're acting differently. So
predictingcarcinogenicity isn'teasy. And I thinkyou've
done a great service to help us identify that one sector,
the mutagenic carcinogens. The assays are good. They
work well, and now we need to get on with identifying
properties ofmany ofthese other nongenotoxic carcin-
ogens.
DR. TENNANT: I'm a little bit surprised that we are
having such acceptance for the performance of Salmo-
nella in identifying mutagens. Frankly, I expected to
hear at least a cautioned ofresponse.
DR. BUrrERWORTH: I think it's an elegant system
and extremely sensitive for picking up mutational
events. It's very, very good. One thing-I'm a little
concernedaboutlookingattheresultsofyourevaluation
onface value. Ifyou'rejustlookingatpluses andminus-
es, the correlation with carcinogenicity is not all that
great. I'm worried that people in industry might begin
to shy away from the short-tern tests and say, Well,
ifI'mnotgoingtopickthisstuffup, whyshould Ibother
using these?
In point of fact, you found about a 50% incidence or
prevalence ofcarcinogens in the system. When I speak
with people in industry, their experience is that the
number ofSalmonella positives in their tests generally
tend to run about 10% or less. They don't seem to have
too manyproblems, andmostpeople, particularly inthe
pharmaceutical area, use batteries of tests without
many problems.
So somehow I hope that one end result ofyour eval-
uation is not to have people shy away from using the
tests because it appears as though they're not predic-
tive. I think they're very good for what they do. Let
me throw this back to you. Why do you think that you
have such a high prevalence ofcarcinogens whereas in
the real world oftesting that the incidence seems to be
fairly low?
DR. TENNANT: Well, I think it has to do with the
very origins ofthe rodent bioassay and the uses forthe
system. It has been used purposefully to attempt to
guess the potential tumorigenicity of substances that
forsomereasonhaveasuspectedtumorigenicpotential.
So there's no doubt that it doesn't represent a cross-
sectionofthechemicaluniverse. Itrepresentstheprod-
uct ofa highly selected process oflooking at chemicals.
And I thinkthat that bias is there and it has to bethere
because otherwise we would bespending alot ofmoney
onalotofrodentsiftherewasn'tthatselectioninvolved.
I think it has worked out very interestingly that, given
the reasons for which chemicals are selected, such a
high proportion have not shown carcinogenicity.
DR. AL SCHUMANN, Dow CHEMICAL: I personally
feelit'simportanttolookatmultipleendpointsingenet-
ic toxicology and not only Salmonella. I think as we try
to get more and more sophisticated in how we assess
risk we need to use each end point as a building block.
As we then build a case from which we can makejudg-
ments on the preponderance of evidence on whether a
material is a genotoxin or not a genotoxin. I would like
to see multiple end points including an initial genetic
tox screen, including getting the material into the test
animal, whether it's by a micronucleus assay or some
type ofin vivo cytogenetic assay.
With respect to Salmonella, ifyou were only looking
at that, there certainly are some instances where you
may get a false picture. One case that comes to mind is
methylene chloride. That material will produce muta-
tions in Salmonella. However, it seems that as you get
into the mammalian cell system and climb the phylo-
genetictree, the evidenceforthegenetictoxicityseems
to diminish, and that includes DNA-binding studies,
Drosophila mutagenesis, micronucleus, UDS, those
types ofthings. Soifone wouldrelyononly Salmonella,
you might get a false picture as to the degree that a
material may be genotoxic.
Going now to a practical, everyday life situation, I
thinkthiswholeareaissomewhatmootwithourcurrent
regulatory framework. The predominating factorinthe
regulatory arenais notthegenetictoxorlackofgenetic
tox. It is what is coming out ofthe tumor bioassay. As
soon as you do get a positive out of that, irrespective
of the dose level or whether you believe it's a genetic
or a nongenetic mechanism, from a risk assessment
framework today, that immediately goes into a unit-
task assessment. We do not have the capability to ade-
quatelyfactorinothermechanisticconsiderationsinthe
whole risk assessment process. That's really where we
need to focus our attention and to evolve over the next
few years as we move ahead in toxicology. We do have
numerous cases where you can't say it is not a geno-
toxin, butyetthepreponderance ofevidencewouldsug-
gest that the genetic activity is so weak that it may be
practically nil and that other factors, such as cell tox-
icity, predominate. Currently we don't have a way of
handling those factors. I realize that you need to be
careful with those types ofcompounds. But we do need
towork as asciencetowardsdifferentiatingthesemate-
rials, because I think they are very different.
DR. TENNANT: Thank you. Heinrich Malling?
DR. HEINRICH MALLING, NIEHS: I know what fan-
tasticworkyouandyourgrouphavedone. But73chem-
icals is not veryrepresentative ofthenumberand class-
es ofchemicals we have in our environment. The ques-
tion still remains as to how effective the Ames test is
in detecting the genotoxic chemicals across the various
classes of chemicals. We are presently beginning to
identify chemicals which are exclusively clastogenic,
such as acrylamide, and it's hard for me to see that the
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Amestestwould detect such chemicals. The clastogenic
compounds seem not to exert any mutagenicity in the
H6PRT-V79 forward mutation system. In contrast,
theyaremutagenicinthetk + mouselymphomasystem
where a complete or partial loss of the tk+ carrying
chromosome results in a detectable mutant. So in the
future it is reasonable to expect carcinogens which are
also mutagens, but which cannot induce reversions in
the Ames test.
DR. TENNANT: Thanks.
DR. SIDNEY GREEN, FDA: I think I would almost
have to come down on the side ofmultitest evidence for
mutagenicity as opposed to relying mainly or solely on
Salmonella for very similar reasons that Heinrich just
addressed. He indicated that there are substances
which Salmonella clearly misses. One that comes to
mind quite readily is benzene. And I think if we just
look at the history in terns of numbers of compounds
that have been tested in numbers of mutagenic assay
systems, there are many instances in which Salmonella
does not detect chemicals that are clearly carcinogens
and mutagens. Forthat reason alone it seems to me we
almost have to rely on multitest evidence again for
mutagenic effects.
DR. TENNANT: Thank you.
UNKNOWN SPEAKER, HEALTH ANDWELFARE, CAN-
ADA: I would also come down for multitesting for one
reason. I don't see where we get off thinking that an
Aroclor-induced rat liver for an S-9 system represents
the real world. It represents the real world to an Aro-
clor-induced rat.
DR. MICHAEL RESNICK, NIEHS: How do we define
a mutagen operationally? Obviously it's something that
causes mutations. Except that I think most of us tend
to focus on DNA damaging-type agents. We really
should also be thinking about something that leads to a
mutation in the classical sense, which is a permanent
and heritable change in the organism. Carl Barrett
alluded to this in his talk on Tuesday. Aneuploidy, of
course, is averyinterestingtype ofmutation. Whenwe
think about chromosomal aneuploidy-that is, the gain
or loss of a chromosome-we're talking about a per-
manent change leading to the loss or gain of a consid-
erable number ofgenes.
Now the target in this case can be DNA, although
we lack strong evidence that DNA is a target for aneu-
ploidy induction. In addition there are many non-DNA
targets, including, for example, tubulin and proteins
associated with centromeres. These are areas that we
are investigating. It turns out that there are a large
number ofchemicals (aproticpolarsolvents, e.g., meth-
ylethylketone, propionitrile, ethylacetate) that are
strong inducers of aneuploidy in yeast and that act on
targets otherthan DNA. Theireffects onothersystems
remain to be established.
So I would say that there are several kinds ofmuta-
gens, only some ofwhich can be detected in Salmonella.
Since Salmonella lacks chromosomal organization typi-
cal ofeukaryotes, it would not be able to detect agents
that act on the segregational apparatus. In support of
this, aprotic polar solvents are not picked up as muta-
gens in the Ames test.
DR. RAJENDRA CHHABRA, NIEHS: Ray, I have
another provocative question after listening to several
people here. How many genetic toxicity end points are
necessary to predict carcinogenicity in vivo? Since
everybody is talkdngaboutmultiple toxicityend points,
I think what we started with was genetic toxicity to
predict invivo toxicity orcarcinogenicity. And here we
are talking about, Okay, let's go and do some more.
More genetic toxicity end points, and let's go into the
in vivo genetic toxicity. Will the cost ofdoing all these
tests be equalto whatwe do invivo, orwillit be more?
DR. TENNANT: Well, if you accept the fact that by
some existing test or combination oftests we can iden-
tify most mutagens, we should be able to identify a
substantial fraction of potential carcinogens. Then we
clearly have agroup ofchemicals thatactthrough some
other not directly mutagenic action or through a muta-
genic mode that involves some change in chromosomal
number or structure. I cannot tell you how many tests
itwillrequireinordertoprospectivelydistinguishthose
sorts of chemicals. Given the range of structures, tox-
icities, and physiologic effects represented among the
nonmutagenic carcinogens, it's very unlikely that they
share many common mechanisms in the way that the
mutagenic chemicals may. Therefore, unless there is
some uniform and fairly limited genetic substrate, like
the oncogenes, for the action of nonmutagens it's very
likely that it is going to take some other combination of
tests to be able to recognize these sorts of chemicals
prospectively.
Now, if we happen to be fortunate in that we have
identified a critical substrate in the genome that is
linked to the emergence ofneoplastic phenotypes (ifwe
have thatinthe oncogenes; and I'mnotcommittingthat
we do, I'm only saying that if that turns out to be the
case) there are numerous and increasinglymore sophis-
ticated approaches to answeringthatquestion. Wemay
find some very surprising ways to address this problem
in the near future. I won't preclude a technological
answer to identifying chemicals that can either specif-
ically nonmutagenically activate oncogenes, modify
theirexpressionoraltertheirchromosomelocation, and
so on. I think there are obtainable answers; the costs
ofdoing that are negotiable. It depends upon what you
want to have as your product. Understanding the pro-
cess might be more valuable than identifying the car-
cinogen.
DR. CHHABRA: Ifwearejustfocusingonfewerprom-
ising tests rather than adding more and more....
DR. TENNANT: It's not just tests we're buying it
seems to me, but we are buyingunderstanding. In this
whole process we have learned much more about not
just about genetic toxicity ofchemicals, but also about
tumorigenicity.
I don't think any of us is saying that any of the in
vitro assays can be used for risk assessment. Possibly
hazard assessment, yes, but not risk assessment. We
don't have the data that tells us that the response in
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the in vitro assay can do anything beyond give us a
qualitative prediction for an in vivo response. The data
available show that ifyou have, for example, a positive
in Salmonella assay, a negative in any future testing
will not negate that positive in the Salmonella assay.
Thus, a positive in the Salmonella assay has some pre-
dictive value for apositive in therodent carcinogenicity
assay, but anegative in amammalian cell assay, wheth-
er it be gene mutation or chromosome aberrations,
doesn't negate that positive.
Many believed that there are chemicals that will only
produce gene mutations and will, therefore, only be
detected in Salmonella assay or mouse lymphoma assay
and not in a chromosome aberration assay. Also that
thereareonlychemicalsthatproducechromosomeaber-
rations and will therefore not be detected in a gene
mutation assay. Therefore, to predict carcinogenicity
you would need both types of assays. There's a good
theoretical basis for this assumption. Unfortunately,
the NCI-NTP data base doesn't support that hypoth-
esis. We are not claiming the Salmonella assay detects
all mutagens or all carcinogens. We know clearly that
we are not mimicking in vivo metabolism and some
chemicals may not be detected. Benzene might be
missed, not because it's only a clastogen, but because
wedo notgenerate theactivemetaboliteinvitro. There
are uses for other tests, but we have to keep in mind
that more tests are not necessarily better tests. We
need tounderstandthedataandunderstandthebiology
ofthe systems.
DR. RoY ALBERT: Well, we've run out of time and
this is the question that you won't have time to discuss.
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